drugs in cancer cells and the tumor microenvironment. This may allow for the design of novel anticancer therapies that concurrently target multiple tumor compartments.
Introduction
Over the past years targeted drugs have profoundly changed the field of cancer therapy, particularly in chronic myeloid leukemia, melanoma and non-small cell lung cancer (NSCLC), which are often driven by oncogenic mutations in kinases. For instance, activating mutations in the epidermal growth factor receptor (EGFR) and fusions of the anaplastic lymphoma kinase (ALK) to echinoderm microtubule-associated protein-like 4 (EML4) in NSCLC have led to FDA approval of targeted therapies with erlotinib and crizotinib, respectively, which confer significant survival benefits to patients with these mutations. In addition, the discovery of various other oncogenic kinase drivers, such as BRAF, HER2, AKT, MEK, ROS1 and RET, (1, 2) has created a tremendous interest in the development of kinase inhibitors as promising novel options for targeted therapies in NSCLC. Oncogenic signaling networks, however, are often highly complex and redundant. Thus, it has been proposed that in order to elicit sufficient and durable clinical responses it may be necessary to target several signaling nodes simultaneously. At the same time, small molecule drugs in general, and kinase inhibitors in particular, are increasingly recognized as being unselective. As off-targets can cause toxic side effects, this may have important therapeutic implications.(3) Conversely, through concurrent targeting of important nodes within complex signaling networks, such off-target effects can also enhance the anticancer activity of kinase inhibitors and lead to entirely novel therapeutic applications, (4, 5) as shown in NSCLC for dasatinib and crizotinib. (6) (7) (8) (9) Given that many of these findings originate from studies with cancer cell lines and considering the controversial discussion regarding differences between in vitro model systems and patient tumors, (10) it is necessary to determine, if off-targets that are functionally relevant in cancer cell lines are also expressed and engaged by the respective drugs in primary tumor tissues. Adding further complexity to the problem, several recent studies illustrated the significant effects that the tumor microenvironment can have on modulating drug sensitivity of cancer cells. (11) (12) (13) It is therefore important to also extend target profiling studies into the tumor microenvironment.
We have recently reported the comprehensive target profile and functional dissection of the mechanism of action of the multikinase inhibitor dasatinib in lung cancer cell lines.(4) To determine how different (or similar) drug target profiles are between cell lines and primary tumor tissues, we here expanded these studies to include lung tumor tissues from human patients and mouse xenografts. Using a combination of mass spectrometry (MS)-based chemical and phosphoproteomics (Figure 1 ), we observed that the majority of targets were conserved between tissues and cell lines.
Several other targets, however, some of which mapped to activated signaling pathways, were only present in tumor tissues. Interestingly, comparison with mouse xenograft tissues suggested that most of these additional targets originated from the tumor microenvironment. In summary, we demonstrate here that kinase inhibitors have complex off-target profiles that encompass both cancer cells and the surrounding tumor microenvironment. In addition, to the best of our knowledge we show for the first time that these drugs simultaneously engage activated signaling pathways in both compartments, and that these can be identified and differentiated by an integrated functional proteomic approach. These findings may have important implications for developing novel therapeutic approaches with kinase inhibitors that incorporate targeting of the tumor microenvironment. (Table S1 ). Affinity chromatography and elution with formic acid were performed as described. (16) After incubation, drug affinity beads were washed with 100 bed volumes of lysis buffer and subsequently with 50 bed volumes of HEPESNaOH buffer. The HEPES-NaOH buffer was composed of 50 mM HEPES (pH 8.0), 0.5 mM EDTA and 100 mM NaCl. All mass spectrometry analyses were performed in duplicate. In addition, biological duplicates of cell line and xenograft samples were generated.
MATERIAL AND METHODS

Biological
Liquid Chromatography and Mass Spectrometry for Protein Identification
Sample preparation was done as previously described. TFA was used for loading and washing the pre-column. After washing, the peptides were eluted by back-flushing onto a 16 cm fused silica analytical column with an inner diameter of 50 μm packed with C18 reversed phase material (ReproSil-Pur 120 C18-AQ, 3 μm, Dr. Maisch GmbH, AmmerbuchEntringen, Germany). The peptides were eluted from the analytical column with a 27 minute gradient ranging from 3 to 30% solvent B, followed by a 25 minute gradient from 30 to 70% solvent B and, finally, a 7 minute gradient from 70 to 100% solvent B at a constant flow rate of 100 nL/min. The analyses were performed in a data-dependent acquisition mode using a top 6 collision-induced dissociation (CID) method. Dynamic exclusion for selected ions was 60 seconds. No lock masses were employed. Maximal ion accumulation time allowed on the LTQ Orbitrap XL was 150 ms for MS n in the LTQ and 1,000 ms in the C-trap. Automatic gain control was used to prevent overfilling of the ion traps and were set to 5,000 in MS n mode for the LTQ, and 10 6 ions for a full FTMS scan. Injection waveforms were activated for both LTQ and Orbitrap. Intact peptides were detected in the Orbitrap at 100,000 resolution and the threshold for switching from MS to MSMS was 2,000 counts.
Data Analysis for Protein Identification
The acquired data were processed with Bioworks v3. ). Following the selection criteria, proteins were grouped on the basis of shared peptides, and only the group reporters were considered in the final output of identified proteins. Spectral conflicts between Mascot and Phenyx peptide identifications were discarded. A false positive detection rate (FDR) of <1% and <0.1% was determined for proteins and peptides, respectively, including the peptides exported with lower scores, by applying the same procedure against a reversed database.
Comparison of the data sets was achieved by an internally-developed program that simultaneously computes the protein groups in all samples and extracts statistical data such as the number of distinct peptides, number of spectra, and sequence coverage. Protein abundance was estimated based on spectral counts using the distributed normalized spectral abundance factor (dNSAF), which adjusts 7 spectral counts for protein length, differentially weighs spectra of unique and shared peptides and normalizes the dSAF values of an individual protein against the sum of all dSAFs in the experiment. (19) For the xenograft samples, the validated results of Mascot and Phenyx and human and mouse searches were merged for each sample group, any spectral conflicts discarded, and grouped according to shared peptides using isobar version 1.5.3.(20)
Phosphoproteomic Analysis
Proteins were reduced with 10 mM dithiothreitol for 30 min at 56°C and alkylated with 22. (CID) and 10 ppm precursor, 25 mmu product (HCD). Other search parameters included maximum of two missed cleavages, fixed modifications for cysteine (carbamidomethyl), variable oxidation on methionine and phosphorylation on tyrosine, serine and threonine. HCD spectra were deconvoluted prior to searching. CID and HCD data were separately filtered to 1% FDR using appropriate mascot cutoffs before combination.
Molecular Modeling
Interactions of sunitinib and dasatinib with NQO2 and PDXK were modeled through molecular modeling templates and co-crystallized ligands were deleted. Induced fit docking was implemented using Glide and Prime to find optimal binding sites and ligand conformations.
RESULTS
Dasatinib and sunitinib target complementary kinome portions in human lung cancers
Following up our previous study in NSCLC cell lines,(4) we selected dasatinib as the drug of choice to also probe primary tumor tissues. To further broaden the scope of our work, we included sunitinib as another multikinase inhibitor with a different in vitro kinase target profile from dasatinib.(23) Importantly, like dasatinib, sunitinib is in advanced clinical development for NSCLC. (7, 24, 25) For both drugs, we have recently described the design, synthesis and validation of close structural analogues suitable for chemical proteomics (c-dasatinib and c-sunitinib, Figure 1B ). These drugs retain activity for the primary kinase targets c-ABL and PDGFRα, respectively, as well as for a plethora of other validated targets. (14, 15) We next assembled a panel of 10 flash-frozen, non-macrodissected NSCLC tissue samples histologically classified as adenocarcinoma. Genotyping for KRAS and EGFR revealed that none of the samples had EGFR mutations, whereas six featured various activating KRAS mutations in codons 12 or 13 (Table S1 ). Total cell lysates of each individual tumor sample were generated and probed with affinity matrices of c-dasatinib and c-sunitinib using gel-free chemical proteomics ( Figure 1A ).(16) Mass spectrometry analysis showed that both drugs interacted with a large number of kinase targets in these patient-derived samples (Table S2) targets ILK and ZAK (MLTK). The strongest sunitinib-specific targets observed were TBK1, AMPKα1 (PRKAA1) and several calcium/calmodulin-dependent protein kinases, particularly CAMK2G and CAMK2D, the latter constituting the most prominent sunitinib target in these samples. In summary, we identified close to 80 protein kinases that interact with dasatinib and sunitinib in primary lung adenocarcinoma tumors. Both drugs displayed largely complementary target profiles with little overlap.
Dasatinib and sunitinib engage protein kinase complexes in human lung cancers
In addition to the protein kinases mentioned above, c-dasatinib and c-sunitinib affinity chromatography recovered a large number of non-kinase proteins. Many of these are likely to interact with the kinases that are direct drug targets. For each tumor sample, we observed about 100 proteins after drug affinity enrichment (Table S2 ). In order to filter non-specific or background proteins, we determined the statistical significance of each protein across all samples to be more specific for dasatinib or sunitinib using a t-test (based on dNSAF values) (Table S2) 
Some of these proteins, particularly the metabolic kinases, may also represent novel direct drug targets. For instance, ADK and PPAT, which are involved in purine metabolism, and FECH and TTR interacted specifically with the dasatinib matrix. PAICS, VAT1, NQO2 and PDXK were selectively purified by the sunitinib matrix. Considering that NQO2 is inhibited by several other kinase inhibitors, (15, 33, 34) it is possible that it is also a direct target of sunitinib. Pyridoxal kinase (PDXK) may be a novel antitarget of sunitinib as it plays an important role in vitamin B6 metabolism and has been recently proposed to be a positive prognostic marker for response of lung cancer to chemotherapy. (35) Molecular docking studies for NQO2 and PDXK support a potential direct binding of sunitinib as compared to dasatinib ( Figure S1 ). In summary, dasatinib and sunitinib target several lung cancer signaling sub-networks through drug-protein and protein-protein interactions. observed in the primary samples (Figure 4 ). For instance, CSK, p38α, ILK and ZAK were amongst the strongest dasatinib targets in both cell lines and the patient samples. Likewise, sunitinib interacted strongly with AMPKα1, several CAMK2s, MAP2K1, MAP2K2 and TBK1 across all samples examined. The latter, however, was less prominent in KRAS-mutant patient samples compared to KRAS-wt tissues and the cell lines. The most notable exceptions to this general trend were EPHA2, AURKA and STK3, STK4, AURKA/B for dasatinib and sunitinib, respectively. These kinases were much more prominent in the cell lines than in the patient samples. Most other kinases were similarly abundant as in the tissue samples.
This was also the case for many of the kinase complex components although some differences were apparent. For instance, several members of the IPP complex (i.e., PARVG and LIMS2/3) were more evident in the tissue samples, whereas AMPK and TBK1 binding partners were only weakly observed or absent in KRAS-mutant tissue samples compared to KRAS-wt tumors and cell lines.
Interestingly, several kinases enriched by the drug affinity matrices from the lung cancer tissues were completely absent in the cell lines. These included several SFKs, such as FGR, LCK, HCK and LYN, which interacted with both drug affinity matrices. RSK1-2 (RPS6KA1/3), MARK2 and PYK2 (PTK2B; in KRAS-mutant samples) were detected as sunitinib-specific targets only in the patient samples.
Similarly, the dasatinib targets SYK, IRAK3, RIPK3, STRADA, EGFR, KIT and PDGFRB were only observed in the tissue samples. BTK, one of the most potent dasatinib targets,(36) was particularly strongly enriched from patient material, but only weakly from cell lines. Several of these kinases, particularly BTK, IRAK3, RIPK3, SYK, LCK, HCK, FGR, etc., are known to be highly expressed in hematopoietic cells, such as B-, T-and myeloid cells ( Figure S2 ).(37) Thus, it is possible that these targets are not derived from the actual lung cancer cells, but rather from tumor-infiltrating immune cells. Also, PDGFRB has been described to be expressed by cancer-associated fibroblasts.(38, 39) Consistently, comparison with previous studies highlights several of these kinases, such as BTK, PDGFRB, LCK and HCK, as some of the most differentially expressed targets between the NSCLC cell lines investigated here and leukemia or melanoma cell lines, whereas most other interactions were maintained (Table S4) 
Differences in drug target profiles between primary and cell line samples can be mostly attributed to the microenvironment
To assess the hypothesis that several prominent dasatinib and sunitinib kinase targets in NSCLC tissue originate from the tumor microenvironment, mouse xenograft models were generated from the human H23 and H292 cell lines. After tumors had developed, the mice were sacrificed, tumors collected and utilized for chemical proteomic experiments with c-dasatinib and c-sunitinib. Exploiting species differences in the amino acid sequences of the proteomes (40, 41) sequential searching of the data against both the human and mouse protein databases allowed the identification of peptides specific to human or mouse, as well as peptides that are indistinguishable due to identical sequences of mouse and human orthologues. This analysis led to the assignment of kinases to both species (Tables S5, S6 ). Albeit not exclusively, the majority of the identified proteins that were common to cell lines and tumor tissues were also identified in the xenograft samples as human. Supporting the concept of exploiting species-specific sequences to determine origin, proteins like albumin and complement C3, which were observed in human tissues, but not cell lines, were of mouse origin in the xenograft samples. This was also the case for various antibodies. Interestingly, dasatinib kinase targets, such as Btk, Pdgfrb and Ripk3, which were present in the tissue, but not the cell line datasets, matched to mouse proteins in the xenograft samples ( Figure 4A) . Similarly, several sunitinib targets, e.g. Fgr, Hck and in the KRAS-mutant sample series also Ptk2b, Ikbke and Rps6ka4, originated from mouse ( Figure   4B ). These observations were particularly apparent for kinases usually expressed in hematopoietic cells or fibroblasts, e.g. Btk, Lck, Fgr, Pdgfrb. In addition, some kinases were only observed in the xenograft samples and only matched to the mouse protein database. Most notable were Pdgfrb (sunitinib), Fyn (dasatinib) and Csf1r (both drugs). This is likely to be attributable to either varying extents of stroma present in the individual samples or to differences between the human and mouse tumor paracrine fashion by stromal cells. In summary, analysis of drug target profiles in NSCLC mouse xenograft samples allowed distinction of human and mouse, i.e. host microenvironment-derived proteins. As the latter also accounted for the major differences between cell line and patient tissue target profiles, this suggested that these drug targets originated also from the tumor microenvironment in the patient tissue samples.
Phosphoproteomics reveals activated proteins and signaling pathways in tumor and microenvironment cells that are targeted by dasatinib and sunitinib
We next investigated the differences between the drug target profiles derived from cell line, tumor tissue and xenograft samples by global phosphoproteomics. In many cases such an approach allows conclusions about the activation status of proteins and signaling pathways. Chemical proteomics requires proteins to be in a native state; but proteins are preferentially denatured for phosphoproteomics. Thus we performed phosphoproteomics subsequent to the drug affinity purification experiments. At the stage of eluting proteins from the drug affinity matrices, proteins were denatured and split into two aliquots. One was analyzed according to the chemical proteomic workflow whilst the other was processed for phosphopeptide enrichment. Despite the low amount of sample available from the drug-binding sub-proteomes, we identified in total 229 phosphoserine, -threonine or -tyrosine phosphosites that mapped to 101 different proteins across both species (Table   S7 ). Amongst these, c-dasatinib and c-sunitinib purified 18 phosphorylated protein kinases each; plus 48 and 47 non-kinase phosphoproteins, respectively. Cross-sample comparison showed that phosphorylation of several sites was widely conserved. For instance, phosphorylation of the direct and indirect dasatinib targets p38α, parvin A and ZAK at Y182, S14 and S637 (corresponding to S638 of murine Zak), respectively, was detected in cell line, xenograft and tumor tissue samples. RIPK2 was also phosphorylated at various sites in many samples. Importantly, phosphorylation of p38α on Y182, ZAK on S637 (autophosphorylation) and RIPK2 on S176 are positively correlated with kinase activity. For sunitinib, phosphorylation of AAK1 particularly at T606 and T620 (corresponding to T523 and T537 of murine Aak1) and MEK2 (MAP2K2) at T394 were observed across most samples. In addition, some phosphorylation events were only detected in samples with KRAS wild-type background, but nonetheless across different sample types. These include AMPKα1 T488, SIK1 S575 (mouse: S577) and on June 20, 2017. © 2014 American Association for Cancer Research. mct.aacrjournals.org Downloaded from STK4 S320. Although the functions of these phosphorylation sites are unknown, this suggests that they may denote more general differences between KRAS-mutant and -wild-type NSCLC. The sites discussed above represent cases in which cell lines, xenografts and patient tissue samples were similar. In addition, some prominent phosphorylation sites (particularly on SIK2, SRSF1 and CAMK2B and D) were exclusively observed in the human tumor tissues. Several of the observed CAMK2D sites represent autophosphorylation events and therefore indicate kinase activity. Phosphorylation of TENC1, a phosphatase that negatively regulates AKT signaling,(42) was only observed in primary human and mouse tissues, but was absent in the cell lines. In the xenograft, this TENC1 phosphopeptide by itself did not allow distinction between human and mouse origin. However, the observation of unphosphorylated Tenc1 peptides with mouse sequences in the KRAS-mutant xenograft samples suggests the possibility that Tenc1 is expressed and phosphorylated in the tumor microenvironment ( Figure 5 ). This may be the case also for several other proteins, most prominently AAK1, RIPK2, ZAK, parvin A, TANK, MEK2 and p38α, which feature unique (unphosphorylated) mouse peptides in the xenograft samples. In support of this, phosphopeptides from Zak, parvin A and Aak1 in the xenograft samples were unambiguously assigned to mouse sequences thereby providing direct evidence that these phosphorylations occur in the tumor microenvironment (Table S7) . Mapping of all phosphoproteins to signaling pathways revealed that dasatinib and sunitinib engage several prominently phosphorylated pathways in human lung cancer tissues (Table S8) . When focusing on the phosphorylation events that correlate with protein activity, this highlights in particular MAPK, integrin and immune signaling as activated pathways that are targeted by the drugs. Interestingly, comparison with mouse-derived drug targets and phosphopeptides suggests that some of these pathways are both activated and targeted in the tumor microenvironment. In summary, phosphoproteomic analysis shows that dasatinib and sunitinib concomitantly target several activated signaling proteins and pathways in tumor cells and the microenvironment. networks towards drug therapy and the support that the tumor microenvironment lends to cancer cells. Selecting the correct pleiotropic kinase inhibitor for a particular tumor, however, still remains a significant challenge. In vitro drug profiling using kinase binding or activity assays provides a wealth of information, (23, 44) but does not cover the entire kinome or account for differential protein expression, protein-protein interactions, (most) gene mutations or post-translational modifications that can modulate kinase activity. We therefore applied a mass spectrometry-based chemical proteomic approach, (45) to determine the unbiased and native protein binding profile across lung cancer patient tumor specimens, cell lines and xenografts. It is important to note that for the targets that are also covered by in vitro profiling panels, we observed good consistency between data from the different technologies, which cross-validates the approaches (Table S9) . (23, 44, 46) In addition, chemical proteomics showed that dasatinib and sunitinib engage several protein complexes through their kinase targets, some of which have been described to play important roles in lung cancer. For instance, sunitinib specifically interacted with TBK1, IKBKE and AMPK complexes. TBK1 has been described to be synthetically lethal with KRAS mutations and is, based on our data, one of the most prominent sunitinib targets.(47) However, this is apparently mostly attributable to relatively high TBK1 expression levels, as in vitro kinase assays, while confirming this interaction, do not suggest that sunitinib would cause sufficiently potent TBK1 inhibition at physiologically relevant concentrations. Color intensities (blue for dasatinib, red for sunitinib) correspond to average dNSAF values and fall into four categories: white: not detected, light: <0.001, medium: 0.001-0.01, dark: >0.01. Grey tones depict proteins in the xenograft experiments, which due to identical sequences of mouse and human peptides cannot be unambiguously assigned to one species. Red arrows indicate the most noteworthy kinases that are likely of tumor microenvironment origin. Kinases with less than 2 unique peptides in a sample set were discarded unless they were observed in a different sample set with at least 2 unique peptides. 
